Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;12(10):6253-6263.
doi: 10.21037/jtd.2020.03.88.

Paraneoplastic syndromes in small cell lung cancer

Affiliations
Review

Paraneoplastic syndromes in small cell lung cancer

Zaid Soomro et al. J Thorac Dis. 2020 Oct.

Abstract

Paraneoplastic syndromes can commonly occur due to lung cancer, especially small cell lung cancer. Frequently paraneoplastic syndromes can precede the diagnosis of the neoplasm or present with limited stage disease. However, these syndromes can also occur at the time of recurrence or metastasis of disease. This review focuses on the epidemiology, pathogenesis, clinical features, and current management of the most common paraneoplastic syndromes encountered in patients with small cell lung cancer. Manifestations of paraneoplastic syndromes in small cell lung cancer include endocrine syndromes with secretion of excess hormones, and neurologic syndromes due to the production of antibodies causing an autoimmune condition. Recent advances have allowed for greater understanding of these syndromes and for the development of improved diagnostic as well as therapeutic tools. Awareness of paraneoplastic syndromes in small cell lung cancer can lead to an earlier diagnosis and recognition of both the condition and in some cases the disease potentially improving the overall survival and prognosis for patients. Further research examining effective methods to improve recovery from neurologic deficits in patients with a paraneoplastic neurologic illness is warranted.

Keywords: Paraneoplastic syndrome; paraneoplastic endocrine syndromes; paraneoplastic neurologic syndromes; small cell lung cancer (SCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.03.88). The series “Small Cell Lung Cancer” was commissioned by the editorial office without any funding or sponsorship. JM reports other from Bayer Pharmaceuticals, outside the submitted work. Other authors have no other conflicts of interest to declare.

References

    1. Guichard A, Vignon G. La polyradiculonévrite cancéreuse métastatique; paralysies multiples des nerfs craniens et rachidiens par généralisation microscopique d'un épithélioma du colutérin. J Med Lyon 1949;30:197-207. - PubMed
    1. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-72. 10.1200/JCO.1997.15.8.2866 - DOI - PubMed
    1. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002;1:294-305. 10.1016/S1474-4422(02)00135-7 - DOI - PubMed
    1. Pelosof LC, Gerber DE. Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clinic Proceedings 2010;85:838-54. 10.4065/mcp.2010.0099 - DOI - PMC - PubMed
    1. Hauber HP. Paraneoplastic syndromes in lung cancer. Pneumologie 2011;65:347-58. 10.1055/s-0030-1256118 - DOI - PubMed